LensAR Inc. Announces Closing of $24 Million in Private Financing to Support Commercial Launch of LensAR Laser System; Announces Executive Changes
March 12, 2012 at 07:30 am EDT
Share
LensAR Inc. announced the closing of a $24 million private financing which included investments from Aisling Capital and Florida Growth Fund (FGF). The financing will support first commercial shipments of the LensAR(TM) Laser System in the United States, Europe and select markets worldwide. Additionally, the financing will support ongoing research and development activities for the LensAR Laser System in additional clinical applications.
The company also announced the appointment of Nick Curtis, the company's Chief Commercial Officer, as interim Chief Executive Officer. Previous CEO Randy Frey will remain a member of the company's Board of Directors and also serve as a consultant to the company.
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
LENSAR, INC. 
